Profile of Prescription Medication in an Internal Medicine Ward
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Anatomical Main Group | Frequency | % N = 11,159 | |
---|---|---|---|
A | Alimentary Tract and Metabolism | 1901 | 17% |
B | Blood and Blood Forming Organs | 2606 | 23.4% |
C | Cardiovascular System | 2283 | 20.5% |
D | Dermatologicals | 28 | 0.3% |
G | Genito Urinary System and Sex Hormones | 144 | 1.3% |
H | Systemic Hormonal Preparations, excl. Sex Hormones and Insulins | 220 | 2.0% |
J | Anti-Infectives for Systemic Use | 1043 | 9.3% |
L | Antineoplastic and Immunomodulating Agents | 17 | 0.2% |
M | Musculo-Skeletal System | 151 | 1.4% |
N | Nervous System | 1913 | 17.1% |
P | Antiparasitic Products, Insecticides, and Repellents | 2 | 0% |
R | Respiratory System | 800 | 7.2% |
S | Sensory Organs | 27 | 0.2% |
V | Various | 24 | 0.2% |
References
- United Nations. World Population Ageing 2019 Highlights; United Nations: New York, NY, USA, 2019. [Google Scholar]
- Divo, M.J.; Martinez, C.H.; Mannino, D.M. Ageing and the epidemiology of multimorbidity. Eur. Respir. J. 2014, 44, 1055–1068. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grina, D.; Briedis, V. The use of potentially inappropriate medications among the Lithuanian elderly according to Beers and EU (7)-PIM list—A nationwide cross-sectional study on reimbursement claims data. J. Clin. Pharm. Ther. 2017, 42, 195–200. [Google Scholar] [CrossRef] [PubMed]
- Stegemann, S.; Ecker, F.; Maio, M.; Kraahs, P.; Wohlfart, R.; Breitkreutz, J.; Zimmer, A.; Bar-Shalom, D.; Hettrich, P.; Broegmann, B. Geriatric drug therapy: Neglecting the inevitable majority. Ageing Res. Rev. 2010, 9, 384–398. [Google Scholar] [CrossRef]
- Martins, I.D.S. Deprescribing no idoso. Rev. Port. Clínica Geral 2013, 29, 66–69. [Google Scholar] [CrossRef]
- Lee, E.A.; Brettler, J.W.; Kanter, M.H.; Steinberg, S.G.; Khang, P.; Distasio, C.C.; Martin, J.; Dreskin, M.; Thompson, N.H.; Cotter, T.M.; et al. Refining the Definition of Polypharmacy and Its Link to Disability in Older Adults: Conceptualizing Necessary Polypharmacy, Unnecessary Polypharmacy, and Polypharmacy of Unclear Benefit. Perm. J. 2020, 24. [Google Scholar] [CrossRef] [Green Version]
- Davies, E.A.; O’Mahony, M.S. Adverse drug reactions in special populations—The elderly. Br. J. Clin. Pharm. 2015, 80, 796–807. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gurwitz, J.H. Polypharmacy: A new paradigm for quality drug therapy in the elderly? Arch. Intern. Med. 2004, 164, 1957–1959. [Google Scholar] [CrossRef] [PubMed]
- Thake, M.; Lowry, A. A systematic review of trends in the selective exclusion of older participant from randomised clinical trials. Arch. Gerontol. Geriatr. 2017, 72, 99–102. [Google Scholar] [CrossRef] [PubMed]
- WHO Collaborating Centre for Drug Statistics Methodology—ATC/DDD. Available online: https://www.whocc.no/atc_ddd_index/ (accessed on 2 February 2021).
- Chocano-Bedoya, P.O.; Bischoff-Ferrari, H.A. DO-HEALTH: Vitamin D3-Omega-3-Home Exercise-Healthy Aging and Longevity Trial—Dietary Patterns in Five European Countries; Springer: Cham, Switzerland, 2019. [Google Scholar]
- Gutierrez Valencia, M.; Martinez Velilla, N.; Lacalle Fabo, E.; Beobide Telleria, I.; Larrayoz Sola, B.; Tosato, M. Interventions to optimize pharmacologic treatment in hospitalized older adults: A systematic review. Rev. Clin. Esp. 2016, 216, 205–221. [Google Scholar] [CrossRef] [PubMed]
- Abegaz, T.M.; Birru, E.M.; Mekonnen, G.B. Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria. PLoS ONE 2018, 13, e0195949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hernandez Martin, J.; Merino-sanjuán, V.; Peris-martí, J.; Correa-ballester, M.; Vial-escolano, R.; Merino-sanjuán, M. Applicability of the STOPP/START criteria to older polypathological patients in a long-term care hospital. Eur. J. Hosp. Pharm. 2018, 25, 310–316. [Google Scholar] [CrossRef] [PubMed]
- Renom-Guiteras, A.; Meyer, G.; Thurmann, P.A. The EU(7)-PIM list: A list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur. J. Clin. Pharm. 2015, 71, 861–875. [Google Scholar] [CrossRef] [Green Version]
- Fahrni, M.L.; Azmy, M.T.; Usir, E.; Aziz, N.A.; Hassan, Y. Inappropriate prescribing defined by STOPP and START criteria and its association with adverse drug events among hospitalized older patients: A multicentre, prospective study. PLoS ONE 2019, 14, e0219898. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- O’Connor, M.N.; Gallagher, P.; Byrne, S.; O’Mahony, D. Adverse drug reactions in older patients during hospitalisation: Are they predictable? Age Ageing 2012, 41, 771–776. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blanc, A.L.; Spasojevic, S.; Leszek, A.; Théodoloz, M.; Bonnabry, P.; Fumeaux, T.; Schaad, N. A comparison of two tools to screen potentially inappropriate medication in internal medicine patients. J. Clin. Pharm. Ther. 2018, 43, 232–239. [Google Scholar] [CrossRef] [PubMed]
- Ma, Z.; Zhang, C.; Cui, X.; Liu, L. Comparison of three criteria for potentially inappropriate medications in chinese older adults. Clin. Interv. Aging 2019, 14, 65–72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roller-Wirnsberger, R.; Thurner, B.; Pucher, C.; Lindner, S.; Wirnsberger, G.H. The clinical and therapeutic challenge of treating older patients in clinical practice. Br. J. Clin. Pharmacol. 2020, 86, 1904–1911. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reeve, E.; Gnjidic, D.; Long, J.; Hilmer, S. A systematic review of the emerging definition of ‘deprescribing’with network analysis: Implications for future research and clinical practice. Br. J. Clin. Pharmacol. 2015, 80, 1254–1268. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Study Population Characteristics | N = 616 |
---|---|
Age (years) | |
Median (Q1–Q3) | 85.0 (78.0–89.0) |
65–74 | 98 (15.9%) |
75–84 | 206 (33.4%) |
≥85 | 312 (50.7%) |
Gender | |
Female | 298 (48.4%) |
Male | 318 (51.6%) |
Hospitalization days | |
Median (Q1–Q3) | 12 (8–20) |
Range (minimum and maximum) | 4–90 |
No. of hospitalizations | |
1 hospitalization | 556 (90.2%) |
2 hospitalizations | 54 (8.8%) |
3 hospitalizations | 6 (1.0%) |
No. of prescribed medicines | |
Median (Q1–Q3) | 17 (13–22) |
Range (minimum and maximum) | 4–50 |
No. of simultaneous medicines prescribed per day | |
Median (Q1–Q3) | 12 (10–14) |
Range (minimum and maximum) | 3–27 |
ICD-10 diagnostics | N = 3873 |
A00-B99—Certain infectious and parasitic diseases | 96 (2.50%) |
C00-D49—Neoplasms | 79 (2.00%) |
D50-D89—Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | 220 (5.70%) |
E00-E89—Endocrine, nutritional and metabolic diseases | 636 (16.40%) |
F0-F99—Mental, Behavioral, and Neurodevelopmental disorders | 140 (3.60%) |
G00-G99—Diseases of the nervous system | 82 (2.10%) |
H00-H59—Diseases of the eye and adnexa | 11 (0.30%) |
H60-H95—Diseases of the ear and mastoid process | 14 (0.40%) |
I00-I99—Diseases of the circulatory system | 829(21.40%) |
J00-J99—Diseases of the respiratory system | 415 (10.70%) |
K00-K95—Diseases of the digestive system | 125 (3.20%) |
L00-L99—Diseases of the skin and subcutaneous tissue | 50 (1.30%) |
M00-M99—Diseases of the musculoskeletal system and connective tissue | 80 (2.10%) |
N00-N99—Diseases of the genitourinary system | 396 (10.20%) |
Q00-Q99—Congenital malformations, deformations, and chromosomal abnormalities | 1 (0.00%) |
R00-R99—Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified | 278 (7.20%) |
S00-T88—Injury, poisoning, and certain other consequences of external causes | 53 (1.40%) |
V00-Y99—External causes of morbidity | 32 (0.80%) |
Z00-Z99—Factors influencing health status and contact with health services | 336 (8.70%) |
Most Prescribed Medicines (3rd Level, Pharmacological Subgroup) | Frequency | % N = 11,159 |
---|---|---|
A02B—Drugs for Peptic Ulcer and Gastro-esophageal Reflux Disease (GORD) | 489 | 4.4% |
A06A—Drugs for Constipation | 381 | 3.4% |
A10A—Insulins and Analogues | 489 | 4.4% |
B01A—Antithrombotic Agents | 746 | 6.7% |
B05B—I.V. Solutions (I.V. solutions used in parenteral administration of fluids, electrolytes and nutrients) | 385 | 3.5% |
B05C—Irrigating Solutions (products used for bladder irrigation, surgical irrigation, incl. instruments) | 707 | 6.3% |
B05X—I.V. Solution Additives (I.V. solution additives are concentrated preparations containing substances used for correcting fluid and electrolyte balance and nutritional status) | 377 | 3.4% |
C03C—High-Ceiling Diuretics | 437 | 3.9% |
C07A—Beta Blocking Agents | 334 | 3.0% |
C09A—ACE Inhibitors | 723 | 6.5% |
J01C—Beta-Lactam Antibacterials, Penicillins | 356 | 3.2% |
N02B—Other Analgesics and Antipyretics | 739 | 6.6% |
N05A—Antipsychotics | 320 | 2.9% |
N05B—Anxiolytics | 298 | 2.7% |
R03A—Adrenergics, Inhalants | 314 | 2.8% |
Coefficient Value | p Value | ||
---|---|---|---|
Hospitalization days | R00-R99—Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified | 0.103 | 0.010 |
S00-T88—Injury, poisoning, and certain other consequences of external causes | 0.106 | 0.009 |
Coefficient Value | p Value | ||
---|---|---|---|
Age | A10A—Insulins and Analogues | −0.111 | 0.006 |
N05B—Anxiolytics | −0.110 | 0.006 | |
B05C—Irrigating Solutions (products used for bladder irrigation, surgical irrigation, incl. instruments | 0.165 | <0.0001 | |
C03C—High-Ceiling Diuretics | 0.171 | <0.0001 | |
J01C—Beta-Lactam Antibacterials. Penicillins | 0.119 | 0.003 | |
R03A—Adrenergics, Inhalants | 0.106 | 0.009 |
Coefficient Value | p Value | ||
---|---|---|---|
Hospitalization days | simultaneous medicines per day | 0.089 | 0.045 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Perpétuo, C.; Plácido, A.I.; Aperta, J.; Herdeiro, M.T.; Roque, F. Profile of Prescription Medication in an Internal Medicine Ward. Healthcare 2021, 9, 704. https://doi.org/10.3390/healthcare9060704
Perpétuo C, Plácido AI, Aperta J, Herdeiro MT, Roque F. Profile of Prescription Medication in an Internal Medicine Ward. Healthcare. 2021; 9(6):704. https://doi.org/10.3390/healthcare9060704
Chicago/Turabian StylePerpétuo, Carla, Ana I. Plácido, Jorge Aperta, Maria Teresa Herdeiro, and Fátima Roque. 2021. "Profile of Prescription Medication in an Internal Medicine Ward" Healthcare 9, no. 6: 704. https://doi.org/10.3390/healthcare9060704
APA StylePerpétuo, C., Plácido, A. I., Aperta, J., Herdeiro, M. T., & Roque, F. (2021). Profile of Prescription Medication in an Internal Medicine Ward. Healthcare, 9(6), 704. https://doi.org/10.3390/healthcare9060704